Figures computed from official regulatory filings — .
Company financials
ProfessionalRevenue, margins, P/E and more come with the Professional plan.
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for NFL BIOSCIENCES only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Market information source · Sep 9, 2026
Open-market timeline · full history
11 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Details | |
|---|---|---|---|---|
| Bruno Lafont | Sell | $32K | AMF | |
| Bruno Lafont |
| Sell |
| $14.7K |
| AMF |
| Bruno Lafont | Sell | $1.6K | AMF |
| Bruno Lafont | Sell | $12.4K | AMF |
| Bruno Lafont | Sell | $58.3K | AMF |
| Bruno Lafont | Exercise | $84.6K | AMF |
| Ignacio Faus | Sell | $22.8K | AMF |
| Ignacio Faus | Sell | $3.5K | AMF |
| Ignacio Faus | Sell | $19K | AMF |
| Ignacio Faus | Sell | $3.6K | AMF |
| Bruno Lafont | Sell | $118.4K | AMF |
| Bruno Lafont | Sell | $165K | AMF |
| Bruno Lafont | Exercise | $54.3K | AMF |
| Ignacio Faus | Exercise | — | AMF |
| Bruno Lafont | Exercise | — | AMF |